Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
|Study Number||Lead Group||Study Title||CIRB||Study Status|
|ACOSOG-Z4099||ACSOG||A Randomized Phase III Study of Sublobar Resection (+/- Brachytherapy) versus Stereotactic Body Radiation Therapy in High Risk Patients with Stage I Non-Small Cell Lung Cancer (NSCLC)<br><br>||Adult CIRB - Late Phase Emphasis||Completed|
|EA6191||ECOG-ACRIN||The BAMM2 (BRAF, Autophagy, MEK inhibition in Melanoma) Study: A Randomized Double Blind Phase II Study of Dabrafenib and Trametinib with or without Hydroxychloroquine in Advanced BRAF V600E/K Melanoma||Adult CIRB - Late Phase Emphasis||Available to Open|
|S1900C||SWOG||A Phase II Study of Talazoparib plus Avelumab in Patients with Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer Bearing Pathogenic STK11 Genomic Alterations (LungMAP Sub-Study)||Adult CIRB - Late Phase Emphasis||Available to Open|
|NRG-HN006||NRG||Randomized Phase II/III Trial of Sentinel Lymph Node Biopsy versus Elective Neck Dissection for Early-Stage Oral Cavity Cancer||Adult CIRB - Late Phase Emphasis||Available to Open|
|CALGB-40302||CALGB||Endocrine Therapy With or Without Inhibition of EGF and HER2 Growth Factor Receptors: A Randomized; Double-Blind; Placebo-Controlled Phase III Trial of Fulvestrant With or Without Lapatinib (GW572016) for Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer||Adult CIRB - Late Phase Emphasis||Completed|
|EA8185||ECOG-ACRIN||Phase 2 Study of Bladder-SparIng ChemoradiatioN with MEDI4736 (Durvalumab) in clinical Stage 3, Node PosItive bladdeR cancEr (INSPIRE)||Adult CIRB - Late Phase Emphasis||Available to Open|
|EA6183||ECOG-ACRIN||A Phase II Neoadjuvant Study of Encorafenib with Binimetinib in Patients with Resectable Locoregional Metastases from Cutaneous or Unknown Primary Melanoma (Stages III N1B/C/D)||Adult CIRB - Late Phase Emphasis||Available to Open|
|CALGB-90202||CALGB||A Randomized Double-Blind; Placebo-Controlled Phase III Study of Early Versus Standard Zoledronic Acid to Prevent Skeletal Related Events in Men with Prostate Cancer Metastatic to Bone||Adult CIRB - Late Phase Emphasis||Completed|
|NSABP-B-39||NSABP||A Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) Versus Partial Breast Irradiation (PBI) for Women with Stage 0; I; or II Breast Cancer||Adult CIRB - Late Phase Emphasis||Completed|
|GOG-0213||GOG||A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel (Or Gemcitabine) Alone or in Combination with Bevacizumab (NSC #704865; IND #113912) followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive; Recurrent Ovarian; Peritoneal Primary and Fallopian Tube Cancer. NCI-Supplied Agents: Bevacizumab (NSC #704865; IND #113912)(12/19/2011) (10/01/12) NCT# 00565851||Adult CIRB - Late Phase Emphasis||Available to Open|